Beta-lactam + beta-lactamase inhibitor
Pregnancy: Use only if benefit outweighs risk; may be associated with necrotising enterocolitis in preterm neonates (ORACLE trial).
Co-amoxiclav (Amoxicillin/Clavulanate)
Brand names: Augmentin
Adult dose
Dose: 375–625 mg every 8 hours oral; 1.2 g every 8 hours IV
Route: Oral or IV
Frequency: Every 8 hours (oral); every 6–8 hours (IV)
Max: 3.6 g/day IV (6 × 600 mg); 1875 mg/day oral
Mild-moderate infections: 375 mg (250/125) or 625 mg (500/125) every 8 hours oral for 5–7 days. IV: 1.2 g (1 g/200 mg) every 8 hours. Hospital-acquired pneumonia: 1.2 g TDS IV. Surgical prophylaxis: 1.2 g IV at induction.
Paediatric dose
Dose: 25 mg/kg
Route: Oral or IV
Frequency: Three times daily
Max: 625 mg/dose oral; 1.2 g/dose IV
Concentration: 125 mg/ml
Oral (125/31 suspension): 1 month–1 year 0.25 mL/kg TDS; 1–6 years 5 mL TDS (250/62 suspension). IV: 30 mg/kg TDS (max 1.2 g).
Dose adjustments
Renal
If eGFR <30: increase interval (every 12 hours); avoid if eGFR <10.
Hepatic
Use with caution in hepatic disease — hepatotoxicity risk with clavulanate.
Paediatric weight-based calculator
Oral (125/31 suspension): 1 month–1 year 0.25 mL/kg TDS; 1–6 years 5 mL TDS (250/62 suspension). IV: 30 mg/kg TDS (max 1.2 g).
Clinical pearls
- Clavulanate inhibits beta-lactamases — active against beta-lactamase producing S. aureus, H. influenzae, Moraxella
- Cholestatic hepatitis more common in older males, especially on long courses — avoid in patients with prior jaundice
- First-choice for bite wounds (human, animal), acute exacerbations of COPD
- Surgically administered IV dose at induction reduces SSI
Contraindications
- Penicillin hypersensitivity
- History of co-amoxiclav-associated jaundice / hepatic dysfunction
- Infectious mononucleosis
Side effects
- GI upset and diarrhoea (more than amoxicillin alone)
- Cholestatic jaundice (delayed — up to 6 weeks post-treatment)
- Rash
- Hypersensitivity / anaphylaxis
- Antibiotic-associated colitis
Interactions
- Warfarin — may increase INR
- Methotrexate — reduced excretion
- Allopurinol — increased risk of rash
Monitoring
- LFTs (prolonged use or if jaundice develops)
- Response to treatment
- C. difficile risk
Reference: BNFc; BNF; NICE NG15 Surgical Site Infections; PHE guidelines. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- SMART Risk Score for Recurrent CVD · Cardiovascular Risk
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- PCSK9 Inhibitor Eligibility Assessment · Lipid Management
- C-Peptide to Glucose Ratio · Diabetes Classification
- Acute Otitis Media Severity (AOM-SOS) · Otitis Media
Pathways
- Infective Endocarditis · ESC 2023 Infective Endocarditis Guidelines; NICE NG41
- Eczema Herpeticum · BAD; NICE CKS
- Suspected Bacterial Meningitis (Adult) · NICE NG240 (2024); NICE NG143 (paeds)
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021
- Returning Traveller — Fever · NaTHNaC; PHE; ESCMID 2018
- Malaria — Diagnosis & Management · PHE 2016; WHO 2023